Shares of CytomX Therapeutics rallying after the company announced it will provide an initial CX-904 Phase 1a clinical data update on May 8 when reporting its Q1 results. The data update is being viewed by the market as sooner than expected. Shares of CytomX are up 98%, or $1.60, to $3.23 in premarket trading.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024
- CytomX Therapeutics upgraded to Neutral from Underweight at JPMorgan
- CytomX Therapeutics doses first patient in CX-2051 Phase 1 study
- CytomX announces $5M milestone triggered in Astellas Pharma TCB collaboration
- CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas